Press Releases

Thermo Fisher Scientific Inc., the world leader in serving science, and Innoforce, a bioinnovation-enabling company, announced they have signed a joint venture agreement to establish a new pharma services facility in Hangzhou, China, for integrated biologics and steriles drug development and manufacturing. The new facility is expected to be completed in 2022. The new state-of-the-art Good Manufacturing Practices (GMP) facility will become part of Thermo Fisher's extensive global

Galapagos NV and OncoArendi Therapeutics SA, announced that they have signed an exclusive collaboration and license agreement for the global development and commercialization of OncoArendi’s OATD-01. OATD-01 is a Phase 2-ready chitotriosidase/acidic mammalian chitinase (CHIT1/AMCase) inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) and other diseases with a fibrotic component.   Lung diseases like IPF are associated with an increased chitinase activ

Iktos, a company specialized in Artificial Intelligence (AI) for new drug design, announced an additional collaboration agreement in AI for new drug design with Merck KGaA, Darmstadt, Germany, a leading science and technology company. In this new collaboration, Iktos’ de novo generative design technology will be used in a structure-enabled context to facilitate the rapid and cost-effective design of an undisclosed Merck KGaA, Darmstadt, Germany drug discovery program. Iktos&rs

Pharma-packaging market leader, SCHOTT KAISHA, has announced an immediate investment of INR 105 crores (~EUR 12 million) into its existing facilities to increase its vial production by 300 million pieces. The decision comes at a time when drug manufacturers around the world are undergoing COVID-19 vaccine trials.  Such complex medications are stored in Type 1 glass vials, which are produced at SCHOTT KAISHA facilities in Gujarat and Daman. The Indo- German venture with the inte

Saillant Therapeutics, an innovative preclinical stage biotechnology company developing promising small molecule-based therapies, today announced that it has obtained Proof of Concept for its lead compound (ST02) indicated for the treatment of heart failure. The compound was tested in a well-established preclinical heart failure model in which it induced a clear reversal to normal of the functional impairments in heart failure, such as Cardiac Output and Ejection Fraction. Moreover, histologi

SOTIO, a clinical stage immuno-oncology company, and Cytune Pharma, both owned by PPF Group, today announced that they will present a late breaking poster highlighting new clinical data on SO-C101 at the Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting to be held virtually November 9-14, 2020. SO-C101 is an IL-15 superagonist currently being investigated in a Phase 1 trial for the treatment of advanced solid tumors. Two additional posters will also be presented summarizing the l

Concert Pharmaceuticals, Inc. announced it has initiated THRIVE-AA1, the first Phase 3 clinical trial to evaluate the efficacy and safety of CTP-543, an oral Janus kinase inhibitor, in adult patients with moderate to severe alopecia areata. The Company expects to report topline results from THRIVE-AA1 in 2022. A second Phase 3 trial, THRIVE-AA2, is expected to begin in the first half of 2021. “Based on the results from our Phase 2 program, we believe CTP-543 has the potential

Decibel Therapeutics, a clinical-stage biotechnology company developing novel restorative gene therapeutics to treat hearing loss and balance disorders, announced exclusive license agreements with the University of Florida (UF) and the University of California, San Francisco (UCSF) for an adeno-associated virus (AAV) gene therapy technology designed to restore hearing to individuals with profound, congenital hearing loss caused by mutations in the otoferlin gene. Otoferlin is a prot

Oxford Gene Technology (OGT), a Sysmex Group Company, has today announced the expansion of its SureSeq™ range of next generation sequencing (NGS) panels to facilitate the interrogation of genes involved in breast and ovarian cancer, and myeloid disorders. The two new panels include a comprehensive 70-gene myeloid panel and a 7-gene breast and ovarian cancer panel that incorporates copy number variation (CNV) detection. Both have been designed based on the most recent literature and with

Novus Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, announced that the first subject has been enrolled in the Phase 2a clinical trial evaluating AT-1501, the Company’s lead product candidate, in adults with amyotrophic lateral sclerosis (ALS). AT-1501 blocks the activation of the CD40L pathway, which has